A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus

Registration

Registration

NCT01733758

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE3

Masking

DOUBLE

Status

COMPLETED

Enrollment

494

Start

2013-02

Primary completion

2014-06

Lead sponsor

GlaxoSmithKline

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG:Albiglutide 30 mg weekly; DRUG:Albiglutide 50 mg weekly; DRUG:Placebo; DRUG:Liraglutide 0.9 mg daily

Results posted

TRUE

Individual participant data sharing

YES

Registered primary outcomes

• Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 [Baseline and Week 24]
• Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24 [Baseline and Week 24]